{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:19:11Z","timestamp":1758478751457,"version":"3.40.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Treatment approach of myasthenia gravis (MG) is still debated; corticosteroids alone or in combination with immunosuppressive agents are the most used drugs. Azathioprine (AZA) has been shown to be effective for MG with a significant steroid-sparing activity, although burdened by side effects. Few studies on methotrexate (MTX) administration showed controversial results. In this cohort, we evaluated the role of MTX as a effective steroid-sparing agent.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Fifteen MG patients treated with MTX, previously treated with AZA for at least 12 months, with poor benefits and uncomfortable side effects AZA related, have been selected. Each patient was evaluated through MG-Activity of Daily Living and Quantitative MG scores 5 times\/yr.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Patients treated with MTX had a significant improvement of MG-Activity of Daily Living and Quantitative MG scores. Furthermore, all patients reduced prednisone dosage, and none complained of side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We suggest MTX is effective and well tolerated and could be considered as a steroid-sparing agent in MG treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000342","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:00:08Z","timestamp":1637622008000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study"],"prefix":"10.1097","volume":"23","author":[{"given":"Carmelo","family":"Rodolico","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Brizzi","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Nicocia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Trimarchi","sequence":"additional","affiliation":[{"name":"Department of Economy, University of Messina, Messina, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Lupica","sequence":"additional","affiliation":[{"name":"Nemo Sud Clinical Centre for Neuromuscular Disorders, University Hospital \u201cG. Martino,\u201d Messina, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olimpia","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"e8497","DOI":"10.1136\/bmj.e8497","article-title":"Myasthenia gravis","volume":"345","author":"Spillane","year":"2012","journal-title":"BMJ."},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3949\/ccjm.80a.13044","article-title":"Myasthenia gravis: newer therapies offer sustained improvement","volume":"80","author":"Li","year":"2013","journal-title":"Cleve Clin J Med."},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"1756286418765591","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000342777","article-title":"Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979\u20132008","volume":"40","author":"Lavrnic","year":"2013","journal-title":"Neuroepidemiology."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000336002","article-title":"Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy","volume":"38","author":"Montomoli","year":"2012","journal-title":"Neuroepidemiology."},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","article-title":"Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial","volume":"1275","author":"Benatar","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia gravis","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol."},{"key":"R13-20250507","first-page":"CD005081","article-title":"Medical and surgical treatment for ocular myasthenia","author":"Benatar","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"R14-20250507","first-page":"CD002828","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology."},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurotherapeutics."},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology."},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest."},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000113809","article-title":"The treatment of severe myasthenia gravis with immunosuppressive agents","volume":"2","author":"Mertens","year":"1969","journal-title":"Eur Neurol."},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology."},{"key":"R24-20250507","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneur.59.5.739","article-title":"Therapies for disorders of the neuromuscular junction","volume":"59","author":"Pruitt","year":"2002","journal-title":"Arch Neurol."},{"key":"R25-20250507","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve."},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2007.134130","article-title":"When the patient fails to respond to treatment: myasthenia gravis","volume":"7","author":"Hilton-Jones","year":"2007","journal-title":"Pract Neurol."},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"Methotrexate in MG Investigators of the Muscle Study Group. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2133.2008.08876.x","article-title":"Effect of folic or folinic acid supplementation on methotrexate associated safety and efficacy in inflammatory disease: a systematic review","volume":"160","author":"Prey","year":"2009","journal-title":"Br J Dermatol."},{"key":"R30-20250507","first-page":"CD005224","article-title":"Immunosuppressive agents for myasthenia gravis","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:04:05Z","timestamp":1746651845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000342","relation":{},"ISSN":["1522-0443"],"issn-type":[{"type":"print","value":"1522-0443"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}